Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 45 of 94 results for autologous

  1. Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  2. COVID-19 rapid guideline: haematopoietic stem cell transplantation (NG164)

    The purpose of this guideline is to maximise the safety of patients who need haemopoietic stem cell transplantation and make the best use of NHS resources, while protecting staff from infection.

    COVID-19 rapid guideline
    Last updated
    28 September 2023

    Sections for NG164

  3. Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy (IPG258)

    Evidence-based recommendations on intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. This involves collecting the solid components of the blood lost during an operation and transfusing it back to the same patient.

    Interventional procedures guidance
    Published
    26 April 2008
    View recommendations

    Sections for IPG258

  4. NICE encourages further data collection, including randomised controlled trials on microstructural scaffold insertion without autologous cell implantation for repairing symptomatic chondral knee defects. Studies should clearly describe patient selection, clinical indications and adjunctive treatments. Outcome measures should include symptom relief, functional ability, long-term outcomes measured by appropriate imaging techniques and patient-reported outcomes.

    randomised controlled trials on microstructural scaffold insertion without autologous cell implantation for repairing symptomatic...

    Research recommendation
    Published
    9 August 2016

  5. Single-step scaffold insertion for repairing symptomatic chondral knee defects (IPG793)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

    Interventional procedures guidance
    Last updated
    5 August 2025
    View recommendations

    Sections for IPG793

  6. Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1098)

    Evidence-based recommendations on isatuximab (Sarclisa) plus bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable.

    Technology appraisal guidance
    Published
    24 September 2025

    Sections for TA1098

  7. NICE encourages further research comparing autologous blood injections (with or without techniques to produce platelet-rich plasma) against established nonsurgical methods for managing tendinopathy. Trials should clearly describe patient selection (including the site of tendinopathy, duration of symptoms and any prior treatments) and document whether a 'dry needling' technique is used. Outcomes should include specific measures of pain, quality of life and function, and whether subsequent surgical intervention is needed.

    IPG438/1 Question NICE encourages further research comparing autologous blood injections (with or without techniques to produce...

    Research recommendation
    Published
    9 June 2015

  8. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)

    Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA677

  9. Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.

    Technology appraisal guidance
    Published
    13 May 2020
    View recommendations

    Sections for TA629

  10. Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma (TA1113)

    Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.

    Technology appraisal guidance
    Published
    3 December 2025
    View recommendations

    Sections for TA1113

  11. Deep dermal injection of non-absorbable gel polymer for HIV-related lipoatrophy (IPG439)

    Evidence-based recommendations on deep dermal injection of non absorbable gel polymer for HIV-related facial lipoatrophy. This involves injecting the gel polymer under the skin to restore the shape and volume of the areas where fat has been lost.

    Interventional procedures guidance
    Published
    23 January 2013
    View recommendations

    Sections for IPG439

  12. Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments (TA954)

    Evidence-based recommendations on epcoritamab (Tepkinly) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.

    Technology appraisal guidance
    Published
    6 March 2024
    View recommendations

    Sections for TA954

  13. Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176]

    Awaiting development Reference number: GID-TA11752 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation (TA311)

    Evidence-based recommendations on bortezomib (Velcade) for treating multiple myeloma before chemotherapy and stem cell transplant in adults.

    Technology appraisal guidance
    Published
    23 April 2014
    View recommendations

    Sections for TA311

  15. Mosaicplasty for symptomatic articular cartilage defects of the knee (IPG607)

    Evidence-based recommendations on mosaicplasty in people with symptomatic articular cartilage defects of the knee. This involves taking healthy cartilage from the edge of the joint and inserting it into drilled tunnels in the damaged site.

    Interventional procedures guidance
    Published
    14 March 2018
    View recommendations

    Sections for IPG607